Breast cancer - hysterectomy and removal of ovaries and tubes

It is well possible that patients diagnosed with breast cancer have been undertreated in the past.

A study to be published soon shows that breast cancer patients who have a hysterectomy and a bilateral salpingo-oohorectomy (BSO) had a 30% increased chance of survival compared to those who preserved uterus and ovaries.

As gynaecological oncologists we regularly see patients with uterine and ovarian cancer who had breast cancer in the past. Some of those poor breast cancer women even had a hysterectomy and had their ovaries preserved. I asked myself if these women could have not only survived their breast cancer but they could have also prevented another gynaecological cancer if they had their uterus, tubes and ovaries removed?

Together with the Cancer Council Queensland and Queensland University of Technology our unit extracted data of 21,000 women diagnosed with primary breast cancer between 1997 and 2008.

We wanted to explore if the “prophylactic” (surgery not related to the treatment of gyn cancer) removal of uterus, tubes and ovaries had an impact on the incidence of gynaecological cancer and if that impact was strong enough to reflect in survival chances. We were also aware of potential side effects from surgery and early menopause and collected data on stroke, DVT/PE and heart attacks as well.

Overall, 7% of women had a hysterectomy and BSO and most of them were premenopausal at the time of surgery. None of those women who had surgery developed gynaecological cancer. Overall survival was significantly better in the group of women who had a hysterectomy and BSO. Especially women who were premenopausal had a 55% higher chance of survival if they had a hysterectomy and BSO.

We do realise that this study comes with some shortcomings: First, the effect was only valid for women who had a hysterectomy and a BSO. Women who only had a BSO did not reap a benefit. I am unable to explain this effect in detail but the most likely reason is an issue with the coding of surgical procedures in Australian hospitals. In a number of instances it is unclear from the surgical procedure code whether one or both ovaries were removed or if they were preserved.

Secondly, data on hormone receptors are not available. If we were to obtain those results, hormone-receptor status would need to be redone for all 21,000 patients, which would be extremely costly. However, the survival advantage for women who had gynaecological surgery is so great that hormone receptor status alone would not be able to explain the differences in survival.

This study is the first study that has shown that hysterectomy and BSO creates survival benefits for breast cancer patients. In non-breast cancer patients, it is generally advised to preserve the ovaries in order to spare our patients hormone-depletion effects. By contrast, prophylactic surgery is well accepted in patients with genetic mutations, such as BRCA1 or BRCA2 or Lynch.

This study also has shown that current breast cancer treatment more than likely delivers under-treatment. The treatment that these women currently receive can be far more effective. 

I spoke to some breast cancer clinicians and they virtually all agree that a large group of breast cancer patients are hesitant to take their hormone (anti-oestrogen) treatment. Chemotherapy alone is not effective enough to stop all endogenous oestrogen production. Periods may stop but oestrogens are still active and provide fuel for the growth of breast cancer cells.

Further, my colleagues also agree that research into better treatments is financially driven. Pharma companies provide funds to research better treatments. Pharma will not fund surgical treatments because they simply don’t derive a benefit from those. And we all know that our National Funding body, the NHMRC is unable to fund surgical trials even if they believe they are absolutely worthy of funding. Hence, if surgical treatments would outperform medical (pharma) treatments, we simply would not know.

The main consequences of this study are twofold. Some clinicians will see this as a justification for the clinical practice that they already do. There are a large number of doctors who recommended prophylactic hysterectomy and BSO after breast cancer. These doctors will now be reassured and will push even harder for their patients to get into adjuvant surgical menopause.

The other consequence is that these data should be validated by independent data sets. One study should not change the entire treatment of a disease. Confirmatory reports should be requested to confirm those findings.

Fact is that these issues touch a very large patient population and the potential gain of adjuvant surgery is enormous.


To subscribe and receive regular blog posts through email - leave your email address here.

Feel free to pass this blog on to colleagues. 

Related Articles

Post your comment

All personal information submitted by you will be used by us in accordance with our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


  • Dr. Gaurav Goel 19/11/2021 10:34pm (2 years ago)

    This information is very useful for us, thank you for giving breast cancer related information.

  • izzat nabillah 02/02/2016 12:23am (8 years ago)

    i have a question sir, the reason why this prophylactic surgery is benefitted rather than only doing BSO or hysterectomy alone remains unclear right until 2 years ago, is the reason still unclear until now?if there's any result of the further research about the reason, can i ask you what is it, sir? thankyou for your concern.

  • Andreas Obermair 17/10/2013 4:04am (11 years ago)

    1. It seems that the benefit of hysterectomy and BSO decreases with increasing patient's age. This is very similar to data showing that prophylactic BSO reduces the risk of breast cancer. The earlier women have a BSO the greater the reduction in breast cancer risk. It makes sense, doesn't it?
    Having said that I would still offer a TLH/BSO to a postmenopausal woman because our data show that her risk of gynaecological cancer is reduced. That constitutes value in itself (even if our data were unable to show a survival benefit).
    2. Aromatase inhibitors (AI) will also target the peripheral oestrogen; that is the oestrogen that gets produced in adipose tissue. However, i don't treat women with breast cancer and am not an expert in AI.

  • dr Gorana Colic 15/10/2013 5:12pm (11 years ago)

    I have to questions: 1. Do you recommend profilactic hysterectomy with BSO also for postmenopausal women with breast cancer ?
    2. After the operation is it necessery to use aromatasa inchibitors for both pre and postmenopausal women (now both group without endogenous hormones)?

RSS feed for comments on this page | RSS feed for all comments